Quote this publication Share Print

HUMIRA (adalimumab), anti-TNF-α immunosuppressant

OPHTHALMOLOGY - New indication
Opinions on drugs - Posted on Jun 09 2017

Reason for request

Extension of indication

Minor clinical progress in the treatment of non-infectious intermediate, posterior and panuveitis

 

  •  HUMIRA has Marketing Authorisation in the treatment of non-infectious intermediate, posterior and panuveitis in adults who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.
  • Despite a moderate efficacy compared to placebo, the therapeutic contribution is minor in the treatment due to the lack of a clinically relevant comparator, long-term safety and efficacy data, and demonstration of an impact in terms of quality of life.

 


Clinical Benefit

Substantial

-


Clinical Added Value

minor

-


Therapeutic use

-

-

Contact Us

Évaluation des médicaments
All our publications